Evidence map›Paper›PMID 41629634›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026

Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [

Ellis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, Ayla Mansur, Atheeshaan Arumuham, Martin Osugo, Tiago Reis Marques, Sameer Jauhar, Ravi Mehrotra, Maja Ranger and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ellis Chika OnwordiDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. e.onwordi@lms.mrc.ac.uk.ORCID http://orcid.org/0000-0001-8108-1225
Thomas WhitehurstDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Ekaterina ShatalinaDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Ayla MansurIQVIA LTD, London, UK.
Atheeshaan ArumuhamDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Martin OsugoDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0002-5462-8464
Tiago Reis MarquesDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0003-0602-7661
Sameer JauharDivision of Psychiatry, Imperial College London, London, UK.
Ravi MehrotraLakeside Unit, West Middlesex University Hospital, West London NHS Trust, London, UK.
Maja RangerWestminster Community Rehabilitation Team & Bluebell Lodge, Central and North West London NHS Foundation Trust, London, UK.
Nikola RahamanKensington Chelsea and Westminster Early Intervention Service, Central and North West London NHS Foundation Trust, London, UK.
Steve M ChurchSouth London and Maudsley NHS Foundation Trust, Camberwell, London, UK.
Eugenii A RabinerInvicro, Burlington Danes Building, London, UK.ORCID http://orcid.org/0000-0003-3612-6687
Roger N GunnInvicro, Burlington Danes Building, London, UK.
Sridhar NatesanDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0001-7499-1714
Abraham Reichenberg *Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Oliver D Howes *Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. oliver.howes@kcl.ac.uk.ORCID http://orcid.org/0000-0002-2928-1972

Funding

RCUK | Medical Research Council (MRC) MC_U120097115RCUK | Medical Research Council (MRC) MR/V013734/1RCUK | Medical Research Council (MRC) MR/W005557/1Wellcome Trust (Wellcome) 094849/Z/10/Z
6 · The paper itself

Abstract

Converging lines of evidence implicate synaptic loss in cognitive impairment associated with schizophrenia. However, it remains unknown whether synaptic terminal density and premorbid intellectual functioning are related in vivo, or whether there are age-related changes in them in schizophrenia. To address this, we investigated whole brain grey matter synaptic vesicle glycoprotein 2A (SV2A) levels and examined their relationship with intellectual functioning and age, in forty-three patients with schizophrenia (SCZ) and 26 healthy volunteers (HV), using [

Indexed as

AgingBrainGray MatterIntelligencePresynaptic TerminalsSchizophreniaAdultCarbon RadioisotopesFemaleHumansMaleMembrane GlycoproteinsMiddle AgedNerve Tissue ProteinsPositron-Emission TomographyPyridines1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-oneCarbon RadioisotopesMembrane GlycoproteinsNerve Tissue ProteinsPyridinesPyrrolidinonesSV2A protein, human

Identifiers

PMID41629634
PMCPMC13125299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.